# DaVita Makes Expanded Hemodialysis Available at Every US Center, With 95% Adoption

> DaVita has made Expanded HD available at every US dialysis center, and physicians prescribed it for 95% of eligible patients within two weeks of the rollout.

- Published: 2026-11-17T11:19:05+00:00
- Section: Product Launches
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-17/davita-expanded-hemodialysis-us-centers
- Source: [PR Newswire](https://www.prnewswire.com/news-releases/davita-expands-availability-of-advanced-dialysis-therapy-to-every-us-center-302941122.html)

## Key takeaways

- DaVita said Expanded HD is now available at every DaVita center in the United States.
- Physicians prescribed Expanded HD for 95% of eligible patients within two weeks of the nationwide rollout.
- Expanded HD uses medium cut-off dialyzers to remove larger middle-molecule toxins while retaining essential proteins.

DaVita said on November 17, 2026 that Expanded hemodialysis is now available at every DaVita center in the United States, and that physicians prescribed it for 95% of eligible patients within two weeks of the nationwide rollout. The kidney care provider announced the milestone in a [PR Newswire](https://www.prnewswire.com/news-releases/davita-expands-availability-of-advanced-dialysis-therapy-to-every-us-center-302941122.html) release.

## How DaVita Rolled Out Expanded HD

[DaVita](https://akta.pro/company-profiles/0000yc5/davita) said Expanded HD removes more of the larger toxins, known as middle molecules, that conventional high-flux hemodialysis leaves behind. The therapy uses medium cut-off dialyzers to clear those larger toxins while retaining essential proteins, and it works with existing dialysis machines and workflows, which the company said enabled a coordinated nationwide rollout.

Medical directors at DaVita's US centers elected to make Expanded HD available when clinically appropriate, while keeping the flexibility to prescribe other dialysis modalities for individual patients. Javier Rodriguez, chief executive officer of DaVita, said: "For patients across the country to gain access to an important advancement in care at the same time, regardless of if they live in a rural or metropolitan community, is something we're incredibly proud of."

Aakash Amin, MD, a medical director for DaVita and nephrologist with Georgia Nephrology, said the decision comes down to removing more of the toxins conventional dialysis leaves behind without adding complexity to a patient's treatment routine. Jacqueline Smith, a DaVita patient in Norfolk, Virginia, said: "I feel better. I can go home and vacuum. I couldn't do that before."

DaVita said it is also evaluating high-volume hemodiafiltration, another option for enhanced clearance that uses specialized machines to remove a large volume of fluid during treatment.

## DaVita's Earlier Kidney Care Investments

DaVita's venture arm co-led a $77.5 million Series A financing for R1 Therapeutics in March 2026 to advance AP306, a pan phosphate transporter inhibitor for hyperphosphatemia in dialysis patients, according to akta.pro [company records](https://akta.pro/company-data). In February 2026, DaVita invested $200 million for a minority stake in Elara Caring alongside Ares Management's Private Equity Group to develop an in-home kidney care model for patients with chronic kidney disease. In December 2025, DaVita launched the X9 startup through its ExploraMed incubator partnership, deploying an FDA-cleared ultrasound-guided cannulation device aimed at reducing dialysis complications and costs.

## DaVita's Recent Conference Appearances

At the 2026 UBS Global Healthcare Conference on November 9, DaVita CFO Joel Ackerman said the company's international and integrated kidney care businesses were growing as expected, with integrated kidney care contributing about 2% to overall growth, Seeking Alpha reported. At the Wolfe Research Healthcare Conference on November 10, Ackerman said third-quarter volume was about 20 basis points below expectations, driven by a missed-treatment rate 20 basis points worse than forecasts and 20 basis points worse than the third quarter of last year, according to Seeking Alpha.

## DaVita's Next Steps for Enhanced Clearance

DaVita said it is exploring approaches that could further expand treatment options, including therapies that delay disease progression, xenotransplantation and advanced care models. The company pointed patients and clinicians to davita.com/middle-molecule for information on middle molecule clearance and its enhanced treatment options.

## Companies in this story

- [DaVita company profile](https://akta.pro/company-profiles/0000yc5/davita) · website: http://www.davita.com

---
News for Agent · https://newsforagent.com/llms.txt
